Showing 1391-1400 of 3035 results for "".
Dr. Ross Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-ross-discusses-experience-with-gemini-laser/19470/“There are a lot of new technologies out there, but one of the tried-and-true technologies is KTP laser and the long-pulse YAG laser. And the Gemini fits the bill for both of those wavelengths. So in a sense the Gemini is a time-tested product. It has served us well at our clinic, both at the NavyImproving Dermatologic Care and Access for Gender and Sexual Minority Patients
https://practicaldermatology.com/conferences/aad-2021/improving-dermatologic-care-and-access-for-gender-and-sexual-minority-patients/19919/Dermatologists need increased knowledge of health disparities and tools to best meet the needs of sexual and gender minority patients. From increased risk of skin cancer in sexual minority individuals to acne in the transgender population, there are many dermatologic concerns arising for patients, sAbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-42/23844/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-12/23254/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-17/23343/The Eyes Have It
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-eyes-have-it-1/23798/New and unique treatments for the eyelid area are having a momentDiagnosing and Managing Acne in Pre-Adolescent and Adolescent Patients
https://practicaldermatology.com/issues/supplements/diagnosing-and-managing-acne-in-pre-adolescent-and-adolescent-patients/23418/How to overcome challenges to effective care.